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ayocardial infarction (MI), defined as an increase in
arkers of myonecrosis 2 to 3 times the upper limit of
ormal, is frequent after coronary procedures and increases
ortality (1,2). Several strategies to prevent this outcome
ave evolved, such as the administration of glycoprotein
Ib/IIIa inhibitors during percutaneous coronary interven-
ions (PCIs) (3). Accumulating evidence suggests that
-hydroxy-3-methylglutaryl coenzyme A reductase inhibi-
ors (statins) are also of value in preventing post-procedural
omplications.
See page 1099
The study of periprocedural statins to prevent cardiac
omplications is a tale of progressive scientific inquiry. In
002, Herrmann et al. (4) found that patients who received
tatins 7 days before PCIs had a lower incidence of MI
ompared with statin nonusers. In 2004, pre-operative
tatin therapy was independently associated with a reduction
n 30-day all-cause mortality and stroke in a cohort of 1,663
atients undergoing primary coronary bypass graft surgery
5). A subsequent retrospective cohort study found that
tatin treatment at the time of PCI was associated with
educed 30- and 60-day mortality, suggesting that lowering
oronary events around the time of intervention improved
urvival (6). The ARMYDA (Atorvastatin for Reduction of
yocardial Damage During Angioplasty) trial was the first
andomized, prospective study to test whether statin treat-
ent decreased myocardial injury and improved outcomes
fter coronary angioplasty. In a cohort of 153 statin-naïve
atients with chronic stable angina, 40 mg atorvastatin 7
ays before PCI reduced post-procedural MI and improved
he 30-day composite outcome of death, MI, or the need for
epeat revascularization (5% vs. 18%; p  0.025). Multivar-
ate logistic regression showed that atorvastatin pre-
reatment was independently associated with a reduction in
eriprocedural creatine kinase-myocardial band elevation
odds ratio: 0.19, 95% confidence interval: 0.05 to 0.57) (7).
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niversity of Michigan Health System, Ann Arbor, Michigan.he ARMYDA–ACS (Atorvastatin for Reduction of Myo-
ardial Damage During Angioplasty–Acute Coronary Syn-
romes) trial studied this effect in those with unstable
oronary syndromes, finding that 80 mg atorvastatin given
2 h before coronary angioplasty decreased the primary
omposite outcome of death, MI, or revascularization (5%
s. 17%, p  0.01) (8). The incidence of post-procedural
I was 5% among statin users compared with 15% in those
n placebo (p  0.04). In 2007, a meta-analysis concluded
hat the risk of periprocedural myocardial necrosis in those
re-treated with statins was substantially lowered (odds
atio: 0.45, 95% confidence interval: 0.33 to 0.62) (9). More
ecently, failure to administer pre-operative statins was
ound to be a predictor of mortality among those undergo-
ng high-risk coronary bypass grafting (10).
Does previous “statin status” affect clinical outcome? In
tatin-naïve patients, the Italian NAPLES (Novel Ap-
roaches for Preventing or Limiting Events) II trial dem-
nstrated that a single pre-procedural 80-mg loading dose
f atorvastatin significantly decreased periprocedural MI
9.5% vs. 15.8%, p  0.014) (11). Among those on long-
erm statin treatment undergoing early PCI for stable
ngina, the ARMYDA–RECAPTURE study found that
cute atorvastatin loading (80 mg 12 h before PCI) reduced
he 30-day incidence of cardiac events from 9.4% to 3.7%
p  0.037), principally due to a reduction in MI (12).
How do periprocedural statins protect myocardium? In
table clinical situations, it is thought that statins mediate
heir primary benefit via low-density lipoprotein reduction.
owever, in acute situations (such as acute coronary syn-
romes or coronary interventions), pure low-density li-
oprotein reduction cannot explain cardiac protection.
Statins act via inhibiting 3-hydroxy-3-methylglutaryl co-
nzyme A reductase. In doing so, they prevent the forma-
ion of the cholesterol precursor mevalonate and produce
mportant downstream nonlipid pleiotropic effects. Meval-
nate depletion limits isoprenoid production and decreases
he formation of Ras and Rho proteins, molecules involved
n intracellular signaling pathways (Fig. 1). Specifically, 2
mportant isoprenoid intermediaries are affected: farnesyl
yrophosphate (FPP) and geranylgeranyl pyrophosphate
GPP). Both FPP and GPP act as intracellular lipid
ttachments for the modification of important proteins
guanosine triphosphate-binding molecules), thus function-
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epletion of FPP and GPP leads to aberrations in a variety
f cellular functions and is believed to be an important
echanism of statin pleiotropicity (13).
The pleiotropic effects of statins are profound. Statins
ugment endothelial function (by up-regulating endothelial
itric oxide synthase), stabilize vulnerable plaque (by de-
reasing matrix metalloproteinase activity), reduce adhesion
olecules (vascular cell adhesion molecule-1, intercellular
dhesion molecule-1, and E-selectin), and decrease circu-
ating biomarkers (e.g., C-reactive protein [CRP]) (13,14).
herefore, before endothelial injury during coronary proce-
Figure 1 Biochemical Basis for the Nonlipid Effects of Statins
Nonlipid lowering (pleiotropic) effects of statins may be mediated by Rho and/or R
which are attenuated via inhibition of 3-hydroxy-3-methylglutaryl (HMG) coenzyme Aures, statin treatment likely mitigates the inflammatory cascade by decreasing vascular reactivity and stabilizing
laque, both at the site of intervention and at other
vulnerable” lesions. These biological effects are thought to
e the basis of periprocedural statin myoprotection.
Should statins routinely be implemented in patients
ndergoing coronary procedures? The answer appears to be
yes.” In their analyses of 4,805 patients in this issue of the
ournal, Winchester et al. (15) show that statin treatment
efore coronary procedures decreases rates of post-
rocedural MI, all-cause mortality, and post-coronary artery
ypass graft atrial fibrillation. Their findings are timely and
ighly relevant in the quest to reduce procedural cardiac
teins,
tase by statin treatment. LDL  low-density lipoprotein.as pro
reducomplications. However, a number of questions remain.
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periprocedural protection? In a substudy of PROVE IT–
TIMI 22 (Pravastatin or Atorvastatin Evaluation and In-
fection Therapy–Thrombolysis In Myocardial Infarction
22), patients undergoing PCI who received high-dose
atorvastatin fared better than those receiving lower doses.
These data support high-dose statin therapy in procedural
settings, although clinical trials also found benefit at lower
doses (16).
. Are certain statins better at procedural protection? The-
oretically, agents with greater influence on Rho or Ras
kinase(s) may be of particular value given the pleiotro-
pism hypothesis. However, this concept remains un-
proven in a clinical setting.
. Is the benefit of pre-procedural statins limited to particular
cohorts? The NAPLES II study showed that atorvastatin
loading reduced periprocedural MI only in those with
elevated CRP, not those with normal CRP levels (11).
Thus, should CRP elevation guide statin treatment? Fur-
ther studies are needed to clarify this paradigm.
. Is there a dark side to periprocedural statins? Unlike
beta-blockers and nitrates, statin treatment does not lead
to readily detectable clinical effects such as low-output
syndromes or bradycardia. Adverse effects may thus be
difficult to detect in clinical trials. At this juncture, there
is little evidence to suggest that statins plus periproce-
dural drugs or anesthesia cause liver or muscle injury.
However, more data (especially in the elderly and those
with pre-existing liver/renal disease), are necessary to
further define this dimension.
Despite their multifaceted properties, statins continue to
emain underused in the treatment of stable and unstable
oronary artery disease. The available evidence creates a
onvincing argument for statin treatment before coronary
rocedures. Given the strong biological rationale and the
um of the clinical data, no patient should undergo coronary
rocedures without statin therapy unless clear contraindica-
ions exist. Indeed, it is time to consider a new indication for
n old friend.
eprint requests and correspondence: Dr. Kim A. Eagle, Uni-
ersity of Michigan, Cardiovascular Center, 1500 East Medical
enter Drive, Suite 2131, Ann Arbor, Michigan 48109-5852.
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